News & Media
Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases
Clinical results and advantage over linezolid in resistance acquisition by Staph aureus among data to be presented at infectious disease meeting
PDF Version Available (30kb)
San Diego, CA, May 6, 2009 – Trius Therapeutics, Inc., a biopharmaceutical company developing bestin-
class drugs for the treatment of serious bacterial infections, announced today that the results of
multiple studies from its lead program, torezolid (Torezolid), will be presented in an oral session and six
poster presentations at the 19th European Congress of Clinical Microbiology and Infectious Diseases
(ECCMID) meeting in Helsinki, Finland May 16-19. Torezolid is a novel antibiotic that recently
completed Phase 2 clinical development with potent activity against gram-positive bacteria, including
methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).
The presentations are as follows:
Saturday, May 16th
Oral Presentation – Lecture Hall 3a (14:54 – 15:06)
- O28: In vivo pharmacodynamics of Torezolid, a new oxazolidinone antibiotic, against methicillinsusceptible and methicillin-resistant Staphylococcus aureus strains; A. Louie, C. Fregeau, W. Liu, H. Conde, R. Kulawy, G. Drusano
Saturday, May 17th
Poster Presentations – New antimicrobials against Gram-positives (13:30 – 14:30)
- P 1091: Effects of food on the pharmacokinetics of Torezolid, a novel oxazolidinone prodrug antibiotic, in healthy adult subjects; KA. Munoz, P. Bien, P. Prokocimer, M. Berry, C. R. Bethune
- P 1092: TR-700, a novel methyltetrazolyl-oxazolidinone, accumulates extensively within human macrophages cells and shows activity towards intraphagocytic linezolid-sensitive and linezolidresistant S. aureus; S. Lemaire, K. Kosowska-Shick, P. Appelbaum, F. Van Bambeke, P. Tulkens
- P 1090: The safety of single ascending oral doses of Torezolid, a novel oxazolidinone prodrug antibiotic; P. Bien, P. Prokocimer, KA. Munoz, J. Bohn
- P 1089: The safety of multiple ascending oral doses of Torezolid, a novel oxazolidinone prodrug antibiotic; P. Bien, P. Prokocimer, KA. Munoz, J. Bohn
- P 1103: Characterization of resistance following serial passage of Staphylococcus aureus in the presence of the novel oxazolidinone TR-700 and linezolid; J. Locke, K. Shaw
- P 1104: Characterization of the novel oxazolidinone TR-700 and linezolid spontaneous mutation frequencies and resistance mechanisms in Staphylococcus aureus; J. Locke, K. Shaw
Copies of these posters will be available on the Trius Web site following the ECCMID meeting:
http://www.triusrx.com/posters.php
About Trius Therapeutics
Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by drug-resistant pathogens. The company’s lead drug candidate, torezolid, is a second generation oral and IV oxazolidinone antibiotic with potent activity against drug-resistant Gram-positive bacterial pathogens including those resistant to Zyvox®, the only marketed antibacterial drug of the oxazolidinone class. Trius has licensed worldwide rights outside of Korea to torezolid from Dong-A Pharmaceuticals. Trius’ pipeline includes two preclinical programs with lead candidates being developed to treat serious infections caused by Gram-negative bacterial pathogens. For more information, visit www.triusrx.com.